临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
13期
1052-1055
,共4页
马妮娜%王婧%李卉惠%张瑞雪%曹邦伟
馬妮娜%王婧%李卉惠%張瑞雪%曹邦偉
마니나%왕청%리훼혜%장서설%조방위
晚期结直肠癌%卡培他滨%奥沙利铂%一线治疗方案
晚期結直腸癌%卡培他濱%奧沙利鉑%一線治療方案
만기결직장암%잡배타빈%오사리박%일선치료방안
Advanced colorectal cancer%Capecitabine%Oxaliplatin%First - line therapy
目的:比较卡培他滨联合奥沙利铂(XELOX)和亚叶酸钙(CF)、5-氟尿嘧啶(5- FU)联合奥沙利铂(FOLFOX6)治疗晚期结直肠癌的近期疗效和不良反应发生率,以指导晚期结直肠癌的治疗。方法将80例患者按照自愿原则分为 X 组和 F 组。X 组采用 XELOX 方案治疗,F 组采用 FOLFOX6方案治疗,统计两组的疗效和不良反应发生情况。结果 X 组完全缓解(CR)、部分缓解(PR)、无变化(NC)和进展(PD)分别有7例、13例、14例和6例,治疗有效率(RR)为50.0%,F 组治疗有效率为47.5%,两组治疗有效率比较无统计学差异( P ﹥0.05)。在不良反应方面,X 组神经毒性、中性粒细胞减少、血小板减少发生率显著低于 F 组( P ﹤0.05),但是手足综合征发生率明显高于 F 组( P ﹤0.05)。结论 XELOX 和 FOLFOX6方案治疗晚期结直肠癌的近期疗效并无显著差异。相比于 F 方案,X 治疗方案用药更为方便,可以显著减少或并不增加除手足综合征外其他不良反应的发生,因此值得在临床中根据患者具体情况考虑优先使用。
目的:比較卡培他濱聯閤奧沙利鉑(XELOX)和亞葉痠鈣(CF)、5-氟尿嘧啶(5- FU)聯閤奧沙利鉑(FOLFOX6)治療晚期結直腸癌的近期療效和不良反應髮生率,以指導晚期結直腸癌的治療。方法將80例患者按照自願原則分為 X 組和 F 組。X 組採用 XELOX 方案治療,F 組採用 FOLFOX6方案治療,統計兩組的療效和不良反應髮生情況。結果 X 組完全緩解(CR)、部分緩解(PR)、無變化(NC)和進展(PD)分彆有7例、13例、14例和6例,治療有效率(RR)為50.0%,F 組治療有效率為47.5%,兩組治療有效率比較無統計學差異( P ﹥0.05)。在不良反應方麵,X 組神經毒性、中性粒細胞減少、血小闆減少髮生率顯著低于 F 組( P ﹤0.05),但是手足綜閤徵髮生率明顯高于 F 組( P ﹤0.05)。結論 XELOX 和 FOLFOX6方案治療晚期結直腸癌的近期療效併無顯著差異。相比于 F 方案,X 治療方案用藥更為方便,可以顯著減少或併不增加除手足綜閤徵外其他不良反應的髮生,因此值得在臨床中根據患者具體情況攷慮優先使用。
목적:비교잡배타빈연합오사리박(XELOX)화아협산개(CF)、5-불뇨밀정(5- FU)연합오사리박(FOLFOX6)치료만기결직장암적근기료효화불량반응발생솔,이지도만기결직장암적치료。방법장80례환자안조자원원칙분위 X 조화 F 조。X 조채용 XELOX 방안치료,F 조채용 FOLFOX6방안치료,통계량조적료효화불량반응발생정황。결과 X 조완전완해(CR)、부분완해(PR)、무변화(NC)화진전(PD)분별유7례、13례、14례화6례,치료유효솔(RR)위50.0%,F 조치료유효솔위47.5%,량조치료유효솔비교무통계학차이( P ﹥0.05)。재불량반응방면,X 조신경독성、중성립세포감소、혈소판감소발생솔현저저우 F 조( P ﹤0.05),단시수족종합정발생솔명현고우 F 조( P ﹤0.05)。결론 XELOX 화 FOLFOX6방안치료만기결직장암적근기료효병무현저차이。상비우 F 방안,X 치료방안용약경위방편,가이현저감소혹병불증가제수족종합정외기타불량반응적발생,인차치득재림상중근거환자구체정황고필우선사용。
Objective To compare the efficacy of capecitabine plus oxaliplatin(XELOX)and leucovorin(CF),5 - fluorouracil(5 -FU)and oxaliplatin(FOLFOX6)in treatment of patients with advanced colorectal cancer and incidence of adverse reactions in order to guide the treatment in these patients. Methods A total of 80 patients were divided into group X and group F according to the principle of voluntary basis with capecitabine and oxaliplatin therapy or leucovorin,5 - fluorouracil and oxaliplatin therapy,and the efficacy and adverse reactions in these 2 groups were statistically analyzed. Results CR,PR,NC and PD in patients of group X were 7,13,14 and 6 cases respectively,and the rate of response(RR)was 50. 0% ,and the rate of response(RR)in group F was 47. 5% ,there was no significant difference( P ﹥ 0. 05)in efficacy of treatment. In terms of adverse reactions,neurotoxicity,neutropenia,and thrombocytopenia in group X were significantly lower than those of group F( P ﹤ 0. 05),but the incidence of hand - foot syndrome in group X was significantly higher than that of group F( P ﹤ 0. 05). Conclu-sion The short term efficacy of capecitabine plus oxaliplatin and leucovorin plus 5 - fluorouracil was not significantly different in treatment of pa-tients with advanced colorectal cancer. In comparison with F program,program X is more convenient in application,in addition to the high inci-dence of hand - foot syndrome,but it can significantly reduce the incidence of adverse reactions,hence it is worthy to be considered in clinical pri-ority according to the specific circumstance of patients .